Related Experiment Video
Updated: Apr 15, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Published on: January 31, 2022
Mechanisms of tolvaptan-induced toxicity in HepG2 cells
Yuanfeng Wu1, Frederick A Beland1, Si Chen1
1Division of Biochemical Toxicology, National Center for Toxicological Research, Food and Drug Administration, Jefferson, AR 72079, USA.
Abstract:
Tolvaptan, a vasopressin receptor 2 antagonist used to treat hyponatremia, has recently been reported to be associated with an increased risk of liver injury. In this study, we explored the underlying mechanisms of hepatotoxicity of tolvaptan using human HepG2 cells. Tolvaptan inhibited cell growth and caused cell death in a concentration- and time-dependent manner. Tolvaptan treatment led to delayed cell cycle progression, accompanied by decreased levels of several cyclins and cyclin-dependent kinases. Tolvaptan was found to cause DNA damage, as assessed by alkaline comet assays; this was confirmed by increased levels of 8-oxoguanine and phosphorylation of histone H2AX. Exposure of HepG2 cells to tolvaptan enhanced cytochrome C release and triggered apoptosis by modulating Bcl-2 family members. The activation of p38 contributed to tolvaptan-mediated apoptosis via down-regulation of Bcl-2. Proteasome inhibition altered tolvaptan-induced cell cycle deregulation and enhanced tolvaptan-induced apoptosis and cytotoxicity. Moreover, tolvaptan treatment induced autophagy. Inhibition of autophagy by knocking-down an autophagy-related gene increased tolvaptan-induced apoptosis and cytotoxicity. Taken together, our findings suggest that the cytotoxicity of tolvaptan results from delayed cell cycle progression, the induction of DNA damage, and the execution of apoptosis. In addition, a number of signaling pathways were perturbed by tolvaptan and played an important role in its cytotoxicity.
Insights
Tolvaptan, a drug for hyponatremia, can cause liver injury. This study shows tolvaptan induces cell death by damaging DNA, disrupting cell cycle, and triggering apoptosis in liver cells.
Area of Science:
- Hepatotoxicity and molecular toxicology.
- Cellular and molecular mechanisms of drug-induced liver injury.
Background:
- Tolvaptan is a vasopressin V2 receptor antagonist used to treat hyponatremia.
- Recent reports link tolvaptan use to an increased risk of liver injury.
Purpose of the Study:
- To investigate the molecular mechanisms underlying tolvaptan-induced hepatotoxicity.
- To elucidate the cellular pathways affected by tolvaptan in liver cells.
Main Methods:
- Utilized human HepG2 cells to study tolvaptan effects.
- Assessed cell viability, cell cycle progression, DNA damage (comet assay, 8-oxoguanine, H2AX phosphorylation), apoptosis (cytochrome C release, Bcl-2 family modulation, p38 activation), proteasome activity, and autophagy.
Main Results:
- Tolvaptan inhibited HepG2 cell growth and induced cell death in a dose- and time-dependent manner.
- Observed delayed cell cycle progression, DNA damage, apoptosis induction, and activation of p38 signaling.
- Tolvaptan treatment modulated proteasome activity and induced autophagy, impacting cytotoxicity.
Conclusions:
- Tolvaptan cytotoxicity stems from cell cycle arrest, DNA damage, and apoptosis induction.
- Perturbation of multiple signaling pathways, including p38, proteasome, and autophagy, contributes to tolvaptan's toxic effects on liver cells.
More Related Videos
Related Concept Videos
Drug Toxicity: Dose-Dependent Reactions
Drug toxicity: Idiosyncratic Reactions
Drug Toxicity: Allergic Reactions
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Drug toxicity: Drug–Drug Interaction
Bioactivation and Tissue Toxicity

